✦ LIBER ✦

Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse’s perspective

✍ Scribed by Krista M. Rubin, Karen Vona, Kathleen Madden, Suzanne McGettigan, Ilana M. Braun

Book ID: 111907387
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 258 KB
Volume: 20
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-012-1473-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Practical guidelines for the management

Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma : Expert opinion

✍ Axel Hauschild; Helen Gogas; Ahmad Tarhini; Mark R. Middleton; Alessandro Testor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Abstract Interferon‐α‐2b (IFNα2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from t

Two different durations of adjuvant ther

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

✍ Johan Hansson; Steinar Aamdal; Lars Bastholt; Yvonne Brandberg; Micaela Hernberg 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 283 KB

Adjuvant therapy with pegylated interfer

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

✍ Jean Jacques Grob; Thomas Jouary; Brigitte Dréno; Julien Asselineau; Ralf Gutzme 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 406 KB

Post-surgery adjuvant therapy with inter

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

✍ Alexander MM Eggermont; Stefan Suciu; Rona MacKie; Wlodzimierz Ruka; Alessandro 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 126 KB

Serum concentrations of pegylated interf

Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

✍ Alexander M. M. Eggermont; Marna G. Bouwhuis; Wim H. Kruit; Alessandro Testori; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 341 KB

Adjuvant therapy with pegylated interfer

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

✍ Alexander MM Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 236 KB